Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Production & Manufacturing
Return to: PBR Home | Production & Manufacturing
Today in Production & Manufacturing

Production & Manufacturing

Mylan to buy Renaissance's dermatology business in $1bn deal Mylan has agreed to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for about $1bn. Production & Manufacturing > OTC > News

Latest Production & Manufacturing News by Sector

Select a sector from the list or browse by sector below:

Fine & Speciality Chemicals

Bayer plans to focus entirely on Life Science businesses
Bayer intends in the future to focus entirely on the Life Science businesses – HealthCare and CropScience – and float MaterialScience on the stock market as a separate company. In this way Bayer is positioning itself as a world-leading company in the field of human, animal and plant health.
Production & Manufacturing > Fine & Speciality Chemicals > News
CordenPharma agrees to purchase Peptisyntha from Solvay
By PBR Staff Writer
International Chemical Investors Group (ICIG) and the Solvay Group have embarked on an agreement, whereby ICIG will purchase Belgium-based Peptisyntha SA, a custom manufacturer of peptides for pharmaceutical use.
Production & Manufacturing > Fine & Speciality Chemicals > News

Process & Production

Amgen receives positive CHMP opinion to extend indication of Kyprolis to treat relapsed multiple myeloma
Amgen announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive opinion to extend the current indication for Kyprolis (carfilzomib) to include treatment in combination with dexamethasone alone for adult patients with multiple myeloma who have received at least one prior therapy.
Production & Manufacturing > Process & Production > News
FDA advisory committee backs approval of Sanofi treatment for adults with type 2 diabetes
By PBR Staff Writer
A US Food and Drug Administration's (FDA) committee recommended the approval of Sanofi's new drug application (NDA) for the investigational fixed-ratio combination of basal insulin glargine 100 Units/mL and GLP-1 receptor agonist lixisenatide to treat adults with type 2 diabetes.
Production & Manufacturing > Process & Production > News

OTC

Dr. Reddy’s Laboratories acquires six OTC brands
Dr. Reddy’s Laboratories has acquired a portfolio of over-the-counter (OTC) brands in the cough-and-cold, pain, and dermatology categories.
Production & Manufacturing > OTC > News
Mylan to buy Renaissance's dermatology business in $1bn deal
By PBR Staff Writer
Mylan has agreed to acquire the non-sterile, topicals-focused specialty and generics business of Renaissance Acquisition Holdings for about $1bn.
Production & Manufacturing > OTC > News

Manufacturing

Kitov announces completion of manufacturing pivotal batches of KIT-302 for registration in US
Kitov Pharmaceuticals announced the completion of manufacturing by Dexcel Pharma of pivotal batches required for registration of KIT-302 with the US Food and Drug Administration (FDA).
Production & Manufacturing > Manufacturing > News
Bristol-Myers Squibb expands Devens biologics facility in Massachusetts
Bristol-Myers Squibb has completed a major expansion at its Devens, Massachusetts biologics facility designed to accelerate development of the company’s growing portfolio of biologics medicines.
Production & Manufacturing > Manufacturing > News